Contact us

We work with groups who have an asset whose dose or tolerability is capped, and we are interested in new use cases for our immunomodulatory small molecules.

Signl is raising a seed round in Q4 2026.

Aaron Esser-Kahn and Jeremiah Kim. Spun out of UChicago.